Screenshot of Glecaprevir and Pibrentasvir for HCV in Kidney Disease

Glecaprevir and Pibrentasvir for HCV in Kidney Disease

A 12-week treatment of glecaprevir and pibrentasvir in stage 4 or 5 chronic kidney disease patients with hepatitis C (HCV) resulted in a high response rate.

https://www.emedevents.com/medical-news/high-sustained-response-rate-for-glecaprevir-pibrentasvir-in-hcv-727369
  • Viesearch
    Moderated and indexed this listing · 4 years ago
  • @emedeventscurator
    Submitted this listing · 4 years ago

Editorial Actions

Feature Edit